You are here

Meeting Highlights

American Society of Hematology Annual Meeting and Exposition

Walter Alexander

Billed as the world’s premier event in malignant and nonmalignant hematology, this year’s American Society of Hematology (ASH) meeting hosted more than 27,000 hematology professionals December 3–6 in San Diego. We review below key sessions on pharmacotherapy clinical trials across a wide span of disease states, including leukemia, graft-versus-host disease, myelofibrosis, multiple myeloma, and sickle cell disease.

Author bio: 
The author is a freelance writer living in New York City.

References

  1. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11;(11):1029–1035.10.1016/S1470-2045(10)70233-3 Epub 2010 Oct 19
  2. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122;(4):515–522.10.1182/blood-2013-02-483750
  3. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32;(5):424–430.10.1200/JCO.2012.48.5797 Epub 2013 Dec 9
  4. Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014;124;(11):4867–4876.10.1172/JCI75328 Epub 2014 Oct 1